5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging
| Autor: | W. Torre, Eduard Monsó, Elena Martínez-Terroba, Enriqueta Felip, Juan P. de-Torres, Luis M. Montuenga, Ana Remirez, Jackeline Agorreta, Carmen Behrens, Miguel Angel Idoate, Jose Luis Ramirez, Ignacio Gil-Bazo, Maria J. Pajares, Ruben Pio, Ignacio I. Wistuba, Rafael Rosell, Laura Millares |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Pulmonary and Respiratory Medicine Oncology medicine.medical_specialty Lung Neoplasms overall survival Kaplan-Meier Estimate Risk Assessment 03 medical and health sciences 0302 clinical medicine signature Internal medicine prognosis Biomarkers Tumor medicine Humans immunohistochemistry squamous cell carcinoma 030212 general & internal medicine disease-free survival Lung cancer Aged Neoplasm Staging Retrospective Studies Lung Prognostic signature business.industry Lung squamous cell carcinoma Reproducibility of Results Middle Aged Prognosis medicine.disease Neoplasm Proteins medicine.anatomical_structure 030228 respiratory system Risk stratification Carcinoma Squamous Cell Prognostic model clinical utility TNM Staging Immunohistochemistry Female business |
| Zdroj: | Thorax r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol instname |
| ISSN: | 1468-3296 |
| Popis: | IntroductionPrognostic biomarkers have been very elusive in the lung squamous cell carcinoma (SCC) and none is currently being used in the clinical setting. We aimed to identify and validate the clinical utility of a protein-based prognostic signature to stratify patients with early lung SCC according to their risk of recurrence or death.MethodsPatients were staged following the new International Association for the Study of Lung Cancer (IASLC) staging criteria (eighth edition, 2018). Three independent retrospective cohorts of 117, 96 and 105 patients with lung SCC were analysed to develop and validate a prognostic signature based on immunohistochemistry for five proteins.ResultsWe identified a five protein-based signature whose prognostic index (PI) was an independent and significant predictor of disease-free survival (DFS) (pConclusionWe have identified and validated a clinically feasible protein-based prognostic model that complements the updated TNM system allowing more accurate risk stratification. This signature may be used as an advantageous tool to improve the clinical management of the patients, allowing the reduction of lung SCC mortality through a more accurate knowledge of the patient’s potential outcome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|